Bacillus subtilis and digestive sensations
What studies of BS50, MB40 and R0179 found for digestive complaints.
Key points
- In healthy adults with mild complaints, BS50 more often produced a prespecified reduction in the combined score for bloating, belching and gas over six weeks: 47.4% versus 22.2% with placebo. No benefit was found for gas separately. [1] See the evidence 1 2
- In adults with frequent or pronounced bloating, MB40 showed no advantage over placebo over four weeks in the severity of bloating, gas or abdominal discomfort. No difference was found for these individual complaints. [2] See the evidence 1 2 3
- In healthy adults with initially mild complaints, R0179 did not improve general well-being or digestive symptoms over four weeks. This result applies to the specific strain and group. [3] See the evidence 1 2
Practical guide
Check the findings and their applicability to your situation.
The strains were studied in different groups and for different symptoms.
Key points
Why these conclusions
Studies of specific strains
Healthy adults aged 30–65 with mild complaints took 2 billion CFU of BS50 daily for six weeks. A decrease of at least two points in the combined weekly score for three symptoms, without a noticeable worsening of any of them, was reported in 47.4% versus 22.2%; no advantage was found for gas separately. Certainty is low — 2 out of 4. [1]
In adults with frequent or pronounced bloating, 5 billion CFU of MB40 daily for four weeks produced no significant advantage for bloating, discomfort or gas. In a small subgroup of men, numerical differences in bloating and days with discomfort or gas also did not reach statistical significance; certainty is 2 out of 4 for the overall group and 1 out of 4 for the subgroup. [2]
Healthy adults took R0179 at doses of 0.1, 1 or 10 billion CFU daily for four weeks. Initial complaints were mild; no improvement in general well-being or digestive symptoms was found, and certainty is low — 2 out of 4. [3]
A reduction of at least 2 points in the combined weekly score for bloating, belching and gas was reported in 47.4% on BS50 and 22.2% on placebo (p=0.024). None of the three complaints could worsen by 1 point or more.
| Parameter | Data |
|---|---|
| Result | A reduction of at least 2 points in the combined weekly score for bloating, belching and gas was reported in 47.4% on BS50 and 22.2% on placebo (p=0.024). None of the three complaints could worsen by 1 point or more. |
| Participants | 76 healthy adults aged 30–65 with mild complaints of bloating, belching or gas; 38 people per group. All completed the study. |
| Form | BS50: capsule containing spores |
| Dose | 2 billion CFU in one capsule daily with the largest meal |
| Dose basis | 2 billion CFU in one capsule daily with the largest meal |
| Comparison | Placebo capsule containing maltodextrin |
| Duration | 6 weeks |
| Certainty | 2/4: One small six-week study with subjective assessment of complaints. The article reports 38 allocated participants per group, but the response percentages in the placebo group correspond to 36. The reason for the different number of observations in this analysis is not explained. |
| Body of evidence | 1 publication described |
| Sources | [1] |
A reduction in gas of at least 1 point was reported in 47.4% on BS50 and 44.4% on placebo. No advantage of the supplement was found (p=0.80).
| Parameter | Data |
|---|---|
| Result | A reduction in gas of at least 1 point was reported in 47.4% on BS50 and 44.4% on placebo. No advantage of the supplement was found (p=0.80). |
| Participants | 76 healthy adults aged 30–65 with mild complaints of bloating, belching or gas; 38 people per group. All completed the study. |
| Form | BS50: capsule containing spores |
| Dose | 2 billion CFU in one capsule daily with the largest meal |
| Dose basis | 2 billion CFU in one capsule daily with the largest meal |
| Comparison | Placebo capsule containing maltodextrin |
| Duration | 6 weeks |
| Certainty | 2/4: One small six-week study with subjective assessment of complaints. The article reports 38 allocated participants per group, but the response percentages in the placebo group correspond to 36. The reason for the different number of observations in this analysis is not explained. |
| Body of evidence | 1 publication described |
| Sources | [1] |
Bloating severity on a scale from 0 to 10 decreased by 3.06 points on MB40 and 3.03 on placebo. The difference between groups was not statistically significant.
| Parameter | Data |
|---|---|
| Result | Bloating severity on a scale from 0 to 10 decreased by 3.06 points on MB40 and 3.03 on placebo. The difference between groups was not statistically significant. |
| Participants | 100 adults aged 18–75 with pronounced or frequent bloating and no significant illnesses. The per-protocol analysis included 91 people: 45 on MB40 and 46 on placebo. |
| Form | MB40 (OPTI-BIOME): capsule containing spores |
| Dose | 5 billion CFU in one capsule every morning |
| Dose basis | 5 billion CFU in one capsule every morning |
| Comparison | Capsule with the same excipients, including maltodextrin, without the probiotic |
| Duration | 4 weeks after a two-week run-in observation period |
| Certainty | 2/4: One small four-week study; the main results presented relate to 91 of the 100 allocated participants. Several complaints and several measures of their severity were assessed. |
| Body of evidence | 1 publication described |
| Sources | [2] |
Abdominal discomfort on a scale from 0 to 10 decreased by 2.34 points on MB40 and 2.77 on placebo. No advantage of the supplement was found.
| Parameter | Data |
|---|---|
| Result | Abdominal discomfort on a scale from 0 to 10 decreased by 2.34 points on MB40 and 2.77 on placebo. No advantage of the supplement was found. |
| Participants | 100 adults aged 18–75 with pronounced or frequent bloating and no significant illnesses. The per-protocol analysis included 91 people: 45 on MB40 and 46 on placebo. |
| Form | MB40 (OPTI-BIOME): capsule containing spores |
| Dose | 5 billion CFU in one capsule every morning |
| Dose basis | 5 billion CFU in one capsule every morning |
| Comparison | Capsule with the same excipients, including maltodextrin, without the probiotic |
| Duration | 4 weeks after a two-week run-in observation period |
| Certainty | 2/4: One small four-week study; the main results presented relate to 91 of the 100 allocated participants. Several complaints and several measures of their severity were assessed. |
| Body of evidence | 1 publication described |
| Sources | [2] |
Gas severity on a scale from 0 to 10 decreased by 2.24 points on MB40 and 2.12 on placebo. The difference between groups was not statistically significant.
| Parameter | Data |
|---|---|
| Result | Gas severity on a scale from 0 to 10 decreased by 2.24 points on MB40 and 2.12 on placebo. The difference between groups was not statistically significant. |
| Participants | 100 adults aged 18–75 with pronounced or frequent bloating and no significant illnesses. The per-protocol analysis included 91 people: 45 on MB40 and 46 on placebo. |
| Form | MB40 (OPTI-BIOME): capsule containing spores |
| Dose | 5 billion CFU in one capsule every morning |
| Dose basis | 5 billion CFU in one capsule every morning |
| Comparison | Capsule with the same excipients, including maltodextrin, without the probiotic |
| Duration | 4 weeks after a two-week run-in observation period |
| Certainty | 2/4: One small four-week study; the main results presented relate to 91 of the 100 allocated participants. Several complaints and several measures of their severity were assessed. |
| Body of evidence | 1 publication described |
| Sources | [2] |
In men, bloating severity decreased by 3.71 points on MB40 and 2.33 on placebo on a scale from 0 to 10. The numerical difference favoring the supplement was not statistically confirmed.
| Parameter | Data |
|---|---|
| Result | In men, bloating severity decreased by 3.71 points on MB40 and 2.33 on placebo on a scale from 0 to 10. The numerical difference favoring the supplement was not statistically confirmed. |
| Participants | Male subgroup: 21 participants who completed the protocol — 11 on MB40 and 10 on placebo. The entire study included 100 adults aged 18–75 with pronounced or frequent bloating. |
| Form | MB40 (OPTI-BIOME): capsule containing spores |
| Dose | 5 billion CFU in one capsule every morning |
| Dose basis | 5 billion CFU in one capsule every morning |
| Comparison | Capsule with the same excipients, including maltodextrin, without the probiotic |
| Duration | 4 weeks after a two-week run-in observation period |
| Certainty | 1/4: A very small subgroup: 11 and 10 men. According to the article, the analysis by sex was planned; there is no separate confirmation in the published registration record. The result in the overall group was null. Numerical differences in men did not reach statistical significance, and several symptoms were tested. |
| Body of evidence | 1 publication described |
| Sources | [2] |
In men, the number of days per week with abdominal discomfort decreased by 1.82 on MB40 and 0.50 on placebo. The difference in changes was 1.32 days; no statistically significant advantage was established.
| Parameter | Data |
|---|---|
| Result | In men, the number of days per week with abdominal discomfort decreased by 1.82 on MB40 and 0.50 on placebo. The difference in changes was 1.32 days; no statistically significant advantage was established. |
| Participants | Male subgroup: 21 participants who completed the protocol — 11 on MB40 and 10 on placebo. The entire study included 100 adults aged 18–75 with pronounced or frequent bloating. |
| Form | MB40 (OPTI-BIOME): capsule containing spores |
| Dose | 5 billion CFU in one capsule every morning |
| Dose basis | 5 billion CFU in one capsule every morning |
| Comparison | Capsule with the same excipients, including maltodextrin, without the probiotic |
| Duration | 4 weeks after a two-week run-in observation period |
| Certainty | 1/4: A very small subgroup: 11 and 10 men. According to the article, the analysis by sex was planned; there is no separate confirmation in the published registration record. The result in the overall group was null. Numerical differences in men did not reach statistical significance, and several symptoms were tested. |
| Body of evidence | 1 publication described |
| Sources | [2] |
In men, the number of days per week with gas decreased by 1.41 on MB40 and 0.35 on placebo. The difference in changes was 1.06 days; no statistically significant advantage was established.
| Parameter | Data |
|---|---|
| Result | In men, the number of days per week with gas decreased by 1.41 on MB40 and 0.35 on placebo. The difference in changes was 1.06 days; no statistically significant advantage was established. |
| Participants | Male subgroup: 21 participants who completed the protocol — 11 on MB40 and 10 on placebo. The entire study included 100 adults aged 18–75 with pronounced or frequent bloating. |
| Form | MB40 (OPTI-BIOME): capsule containing spores |
| Dose | 5 billion CFU in one capsule every morning |
| Dose basis | 5 billion CFU in one capsule every morning |
| Comparison | Capsule with the same excipients, including maltodextrin, without the probiotic |
| Duration | 4 weeks after a two-week run-in observation period |
| Certainty | 1/4: A very small subgroup: 11 and 10 men. According to the article, the analysis by sex was planned; there is no separate confirmation in the published registration record. The result in the overall group was null. Numerical differences in men did not reach statistical significance, and several symptoms were tested. |
| Body of evidence | 1 publication described |
| Sources | [2] |
No improvement in general well-being was found. Mean scores for six groups of complaints on a daily questionnaire remained below 1 point on a scale from 0 to 6; initial complaints were mild.
| Parameter | Data |
|---|---|
| Result | No improvement in general well-being was found. Mean scores for six groups of complaints on a daily questionnaire remained below 1 point on a scale from 0 to 6; initial complaints were mild. |
| Participants | 83 healthy adults aged 18–50 were allocated to four groups. A total of 81 completed the study: 21 at the 0.1 billion dose, and 20 each at the 1 and 10 billion doses and on placebo. |
| Form | R0179: capsule; 75% spores and 25% normal growing bacterial cells |
| Dose | 0.1, 1 or 10 billion CFU in one capsule daily, at the end of a meal |
| Dose basis | 0.1, 1 or 10 billion CFU in one capsule daily, at the end of a meal |
| Comparison | Matching placebo capsule |
| Duration | 4 weeks of intake; one additional week of observation after stopping |
| Certainty | 2/4: Small groups of approximately 20 people each; the study primarily assessed tolerability. Initial complaints were mild, so the ability to detect improvement was limited. |
| Body of evidence | 1 publication described |
| Sources | [3] |
Digestive symptoms on the GSRS questionnaire did not improve. Mean scores for individual symptom groups were 1.1–1.9 on a scale from 1 to 7, where 1 means no discomfort.
| Parameter | Data |
|---|---|
| Result | Digestive symptoms on the GSRS questionnaire did not improve. Mean scores for individual symptom groups were 1.1–1.9 on a scale from 1 to 7, where 1 means no discomfort. |
| Participants | 83 healthy adults aged 18–50 were allocated to four groups. A total of 81 completed the study: 21 at the 0.1 billion dose, and 20 each at the 1 and 10 billion doses and on placebo. |
| Form | R0179: capsule; 75% spores and 25% normal growing bacterial cells |
| Dose | 0.1, 1 or 10 billion CFU in one capsule daily, at the end of a meal |
| Dose basis | 0.1, 1 or 10 billion CFU in one capsule daily, at the end of a meal |
| Comparison | Matching placebo capsule |
| Duration | 4 weeks of intake; one additional week of observation after stopping |
| Certainty | 2/4: Small groups of approximately 20 people each; the study primarily assessed tolerability. Initial complaints were mild, so the ability to detect improvement was limited. |
| Body of evidence | 1 publication described |
| Sources | [3] |
Information from the source
In a study of 5 billion CFU of MB40 daily, adverse events were reported in both groups. Those possibly related to the supplement included constipation, abdominal discomfort, diarrhea, gas and dry mouth; they had resolved by the end of the study. In a separate tolerability study of 10 billion CFU of MB40 daily, one participant experienced vomiting and chills, which the authors considered probably related to intake. They resolved within 31 hours. In the R0179 study, one participant in the 10 billion CFU group discontinued after itching and skin redness; a causal relationship was not established. In people with severe illness, weakened immunity or a central venous catheter, live probiotics require individual medical assessment because of the risk of infection. The FDA issued a separate warning for hospitalized preterm infants. This information applies to probiotics in general, not to an established infection rate for each B. subtilis strain. [2] [4] [5] [3] [6]
Information from the source
| Name | Description | Sources |
|---|---|---|
| Live strains in capsules | BS50, MB40, R0179 and CU1 are different strains with their own studies. On the label, the strain code, CFU count through the end of shelf life and storage conditions matter. A higher CFU count alone does not mean a greater effect. | [1] [2] [3] [7] [4] |
| BG01-4 after heating | The study used a sachet containing 1 g of powder after heat treatment. The article also reports 5 billion CFU, but does not explain whether this figure refers to the state before or after heating. It is therefore not presented here as a dose of live bacteria. | [8] |
| Food cultures | Natto and other fermented foods have their own food strains. Their presence in a product does not establish an effect of BS50 or MB40. Preparation can change the number of live bacteria; in a natto study, boiling reduced it. | [9] [10] [11] [12] [13] |
Sources
- The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/36269141/
- A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating. https://pubmed.ncbi.nlm.nih.gov/31719214/
- Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. https://pubmed.ncbi.nlm.nih.gov/25062611/
- Probiotics — Health Professional Fact Sheet (NIH ODS). https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/
- FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. https://www.fda.gov/news-events/press-announcements/fda-raises-concerns-about-probiotic-products-sold-use-hospitalized-preterm-infants
- Safety Assessment of Bacillus subtilis MB40 for Use in Foods and Dietary Supplements. https://pubmed.ncbi.nlm.nih.gov/33668992/
- Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. https://pubmed.ncbi.nlm.nih.gov/26640504/
- Bacillus Subtilis (BG01-4(TM)) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/37960143/
- Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141369
- Characterization of Bacillus subtilis strains in Thua nao, a traditional fermented soybean food in northern Thailand. https://doi.org/10.1111/j.1472-765X.2006.01966.x
- Genotyping of starter cultures of Bacillus subtilis and Bacillus pumilus for fermentation of African locust bean (Parkia biglobosa) to produce Soumbala. https://pubmed.ncbi.nlm.nih.gov/14698101/
- Co-production of surfactin and a novel bacteriocin by Bacillus subtilis subsp. subtilis H4 isolated from Bikalga, an African alkaline Hibiscus sabdariffa seed fermented condiment. https://www.sciencedirect.com/science/article/pii/S0168160513000421
- Treatment of natto, a fermented soybean preparation, to prevent excessive plasma vitamin K concentrations in patients taking warfarin. https://pubmed.ncbi.nlm.nih.gov/17190098/
Methodology: Subpages evidence-led supplement pipeline v1